These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 38881600)
1. Prosthetic Visual Acuity with the PRIMA Subretinal Microchip in Patients with Atrophic Age-Related Macular Degeneration at 4 Years Follow-up. Muqit MMK; Le Mer Y; Olmos de Koo L; Holz FG; Sahel JA; Palanker D Ophthalmol Sci; 2024; 4(5):100510. PubMed ID: 38881600 [TBL] [Abstract][Full Text] [Related]
2. Prosthetic Visual Acuity with the PRIMA System in Patients with Atrophic Age-related Macular Degeneration at 4 years follow-up. Muqit M; Mer YL; de Koo LO; Holz FG; Sahel JA; Palanker D medRxiv; 2023 Nov; ():. PubMed ID: 38014146 [TBL] [Abstract][Full Text] [Related]
3. Photovoltaic Restoration of Central Vision in Atrophic Age-Related Macular Degeneration. Palanker D; Le Mer Y; Mohand-Said S; Muqit M; Sahel JA Ophthalmology; 2020 Aug; 127(8):1097-1104. PubMed ID: 32249038 [TBL] [Abstract][Full Text] [Related]
4. Safety Results for Geographic Atrophy Associated with Age-Related Macular Degeneration Using Subretinal Cord Blood Platelet-Rich Plasma. Rizzo S; Savastano MC; Falsini B; Bernardinelli P; Boselli F; De Vico U; CarlĂ MM; Giannuzzi F; Fossataro C; Gambini G; Crincoli E; Ferrara S; Ripa M; Killian R; Rizzo C; Valentini CG; Orlando N; Placidi G; Teofili L; Savastano A Ophthalmol Sci; 2024; 4(6):100476. PubMed ID: 39149709 [TBL] [Abstract][Full Text] [Related]
5. Improved Structure and Function in Early-Detected Second-Eye Neovascular Age-Related Macular Degeneration: FASBAT/Early Detection of Neovascular Age-Related Macular Degeneration Report 1. Gale RP; Airody A; Sivaprasad S; Hanson RLW; Allgar V; McKibbin M; Morland AB; Peto T; Porteous M; Chakravarthy U; Ophthalmol Retina; 2024 Jun; 8(6):545-552. PubMed ID: 38171416 [TBL] [Abstract][Full Text] [Related]
7. Comparison of visual acuity in macular degeneration patients measured with snellen and early treatment diabetic retinopathy study charts. Falkenstein IA; Cochran DE; Azen SP; Dustin L; Tammewar AM; Kozak I; Freeman WR Ophthalmology; 2008 Feb; 115(2):319-23. PubMed ID: 17706288 [TBL] [Abstract][Full Text] [Related]
8. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ; Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095 [TBL] [Abstract][Full Text] [Related]
9. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG; Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282 [TBL] [Abstract][Full Text] [Related]
10. Magnitude of Visual Acuity Change with ETDRS versus Snellen Testing in Clinical Trials: Implications for Clinic-Based Outcomes. Salabati M; Huang C; Kamalipour A; Yu HJ; Mahmoudzadeh R; Jeng-Miller K; Chen E; Shah CP; Wykoff CC; Hsu J Ophthalmol Sci; 2024; 4(2):100372. PubMed ID: 37868803 [TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). Kaiser PK Trans Am Ophthalmol Soc; 2009 Dec; 107():311-24. PubMed ID: 20126505 [TBL] [Abstract][Full Text] [Related]
12. Maintenance of Vision Needed to Drive after Intravitreal Anti-VEGF Therapy in Patients with Neovascular Age-related Macular Degeneration and Diabetic Macular Edema. Emami-Naeini P; Garmo V; Boucher N; Fernando R; Menezes A Ophthalmol Retina; 2024 Apr; 8(4):388-398. PubMed ID: 37866681 [TBL] [Abstract][Full Text] [Related]
14. Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. Sunness JS; Rubin GS; Broman A; Applegate CA; Bressler NM; Hawkins BS Ophthalmology; 2008 Sep; 115(9):1480-8, 1488.e1-2. PubMed ID: 18486216 [TBL] [Abstract][Full Text] [Related]
15. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Jaffe GJ; Martin DF; Toth CA; Daniel E; Maguire MG; Ying GS; Grunwald JE; Huang J; Ophthalmology; 2013 Sep; 120(9):1860-70. PubMed ID: 23642377 [TBL] [Abstract][Full Text] [Related]
16. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Spielberg L; Leys A Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659 [TBL] [Abstract][Full Text] [Related]
17. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians. Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109 [TBL] [Abstract][Full Text] [Related]
18. Long-term observations of macular thickness after subretinal implantation of a photovoltaic prosthesis in patients with atrophic age-related macular degeneration. Muqit MMK; Mer YL; Holz FG; Sahel JA J Neural Eng; 2022 Oct; 19(5):. PubMed ID: 36174540 [No Abstract] [Full Text] [Related]
19. Relationship of Topographic Distribution of Geographic Atrophy to Visual Acuity in Nonexudative Age-Related Macular Degeneration. Shen LL; Sun M; Ahluwalia A; Young BK; Park MM; Toth CA; Lad EM; Del Priore LV Ophthalmol Retina; 2021 Aug; 5(8):761-774. PubMed ID: 33212271 [TBL] [Abstract][Full Text] [Related]
20. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Brown DM; Chen E; Mariani A; Major JC; Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]